Recurrence Score May Cut Costs for High-Risk Breast Cancer Care

WEDNESDAY, April 10, 2019 -- Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news